RET and cancer: Broad, hybrid capture–based next-generation sequencing using the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets—MSK-IMPACT—and Illumina HiSeq 2500 (Illumina, San Diego, CA)17 identified an EML4-RET fusion (Fig 1B) in addition to a TP53 p.P142Tfs*5 frameshift mutation.